Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Epigenetic Approaches in Drug Discovery, Development and Treatment
| Epigenetic Approaches in Drug Discovery, Development and Treatment |
| Autore | Giri Shibashish |
| Pubbl/distr/stampa | Frontiers Media SA, 2020 |
| Descrizione fisica | 1 electronic resource (130 p.) |
| Soggetto topico |
Science: general issues
Pharmacology |
| Soggetto non controllato |
Epigenome
Diseases epigenome Histone variants histone modification DNA methylation small molecules oncology non-coding RNA Drug transporters epigenetic biomarkers organoids model |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557215603321 |
Giri Shibashish
|
||
| Frontiers Media SA, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Microbial engineering for therapeutics / / Mrutyunjay Suar, Namrata Misra and Chandravanu Dash, editors
| Microbial engineering for therapeutics / / Mrutyunjay Suar, Namrata Misra and Chandravanu Dash, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (377 pages) |
| Disciplina | 610.28 |
| Soggetto topico |
Biomedical engineering
Medical microbiology Microbial biotechnology |
| ISBN | 981-19-3979-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Editors and Contributors -- Part I: Introduction to Microbial Engineering -- 1: Exploring the Potential of Microbial Engineering: The Prospect, Promise, and Essence -- 1.1 Introduction: The Prospect -- 1.1.1 Origins of the Use of Microbes for Disease Therapy -- 1.2 Toolbox for Engineering Living Therapeutics -- 1.2.1 Chassis Selection -- 1.2.2 Sense and Control -- 1.2.3 Memory Circuits -- 1.2.4 Production and Delivery of Therapeutic Molecules -- 1.2.4.1 Genetic Actuators: Reporters -- 1.2.5 Biocontainment and Biosafety -- 1.2.6 Probiotics Collection at the Registry of Standard Biological Parts -- 1.3 Engineering Microbes for Human Health: The Promise -- 1.4 Engineering Microbes to Rewire Metabolism -- 1.4.1 Phenylketonuria -- 1.4.2 Hyperammonemia -- 1.4.3 Diabetes -- 1.5 Engineered Bacteria to Modulate the Immune System -- 1.5.1 Inflammatory Bowel Disease -- 1.5.2 Mucositis -- 1.6 Engineering Probiotics for the Treatment of Bacterial Infections -- 1.6.1 Pseudomonas aeruginosa -- 1.6.2 Vibrio cholerae -- 1.6.3 Salmonella Species -- 1.6.4 Enterococcus Species -- 1.7 Engineering Probiotics for Disease Diagnosis -- 1.7.1 Quorum-Sensing System -- 1.7.2 Biosensing to Detect Gut Inflammation -- 1.7.3 Biosensing for Cancer Diagnosis -- 1.8 Future Prospects: The Essence -- References -- Part II: Microbial Engineering Approaches -- 2: Role of System Biology in Microbial System -- 2.1 Introduction -- 2.2 Industrial Microbial Systems -- 2.2.1 Production of Anti-Listeria Chemicals -- 2.2.2 Isobutanol Production -- 2.2.3 Food Microbiology -- 2.3 Plant Microbial Systems -- 2.3.1 Bioremediation -- 2.3.2 Plant-Associated Microbiomes -- 2.4 Biomedical Microbial Systems -- 2.4.1 Metabolic Network Modelling of the Gut Microbiome -- 2.4.2 Studying Host-Pathogen Interaction -- 2.4.3 Adaptation of Microbes to Nutritional Conditions Inside the Cell.
2.4.4 Modelling the Population Dynamics of the Microbes -- 2.4.5 Vaccine Development -- 2.5 Challenges and Ways to Overcome Them -- References -- 3: Synthetic Biology: Refining Human Health -- 3.1 Introduction -- 3.2 Applications of Synthetic Biology in Human Health -- 3.2.1 Pathogen Mechanisms -- 3.2.2 Immune Systems -- 3.2.3 Vaccines -- 3.2.4 Drug Discovery -- 3.2.5 Drug Production and Drug Delivery -- 3.2.6 Breaking Bacterial Resistance by Designer Phages -- 3.3 Applications of Engineered Synthetic Ecosystems -- 3.3.1 Targeting Microbial Communities in Engineering -- 3.3.2 Biosensors and Biosensing -- 3.3.3 Biodegradation -- 3.3.4 Biosynthesis -- 3.3.5 Microbial Biofuel Production -- 3.4 Some Limitations of Synthetic Biology -- 3.4.1 Biosafety Concerns -- 3.4.2 Allergies -- 3.4.3 Carcinogens -- 3.4.4 Pathogenicity or Toxicity -- 3.4.5 Change or Depletion of the Environment -- 3.4.6 Horizontal Gene Transfer -- 3.5 Conclusion and Future Prospect in Synthetic Biology for Humans -- References -- 4: Gut Microbiome and Obesity: Connecting Link -- 4.1 Introduction to Obesity -- 4.1.1 Obesity and Comorbidities -- 4.1.2 Metabolic Syndrome -- 4.2 Etiologies of Obesity -- 4.2.1 Polygenic Nature of Obesity: Leptin and Ghrelin -- 4.2.2 Incidence and Prevalence -- 4.2.3 Difference Between Agrarian and Western Diet -- 4.2.4 Diet and Microbiome -- 4.2.5 Connection Between Diet and Disease -- 4.3 Current Interventions to Obesity -- 4.3.1 Non-pharmacological Interventions -- 4.3.2 Pharmacological Interventions (Fig. 4.2) -- 4.3.2.1 Orlistat (Xenical) -- 4.3.2.2 Phentermine and Topiramate Extended Release -- 4.3.2.3 Lorcaserin (Belviq) -- 4.3.2.4 Bupropion SR and Naltrexone SR (Contrave) -- 4.3.2.5 Liraglutide (Saxenda, Victoza) -- 4.3.3 Bariatric Surgery -- 4.3.4 Shortcomings of Intervention -- 4.4 Gut Microbiome and Obesity. 4.4.1 Gut Microbiome and Energy Harvest from Foods -- 4.4.2 Firmicutes and Bacteroidetes Phyla -- 4.4.3 Gut Microbiome and Leaky Gut Syndrome -- 4.5 Inflammation and Obesity -- 4.5.1 Low-Grade Chronic Inflammation -- 4.5.2 Inflammation and Metabolic Consequences -- 4.5.3 Vagal Afferent Neurons -- 4.6 New Frontiers in the Treatment of Obesity and Associated Comorbidities -- 4.6.1 Vagal Nerve Blockade -- 4.6.2 Fecal Microbiota Transplant -- 4.7 Conclusion -- References -- 5: Engineering Microbes for Smart Diagnostics and Lab-on-Chip -- 5.1 Introduction -- 5.2 Microbial Engineering -- 5.2.1 Factors Affecting the Choice of Microbial Species for Diagnostics and Therapeutics -- 5.2.2 Engineered Microbes as Sensors for Diagnosis -- 5.2.3 Genetic Circuits in Microbial Diagnostics -- 5.3 Microfluidics and Microbial Engineering -- 5.3.1 Engineered Microbes as a Functional Part of Microfluidics -- 5.3.2 Toxicity Detection -- 5.3.3 Sensing of Biomolecules -- 5.4 Microbial Engineering Facilitated by Microfluidics -- 5.4.1 DNA Recombination -- 5.4.2 Transformation -- 5.4.3 Microbial Selection/Screening -- 5.4.4 Genotyping -- 5.4.5 Phenotyping -- 5.5 Microbial Consortia Engineering in Microfluidics -- 5.6 Future Scope of Microfluidics and Microbial Engineering in Diagnostics -- 5.7 Conclusion -- References -- 6: Bacteriophage and Virus Engineering -- 6.1 Introduction -- 6.2 Engineering Bacteriophage for Biotechnological Applications -- 6.2.1 Phage for Delivery of Drug Molecules -- 6.2.2 Phage to Deliver Peptides/Protein Molecules -- 6.2.3 Phage for Gene Therapy -- 6.2.4 Phage Display Technology -- 6.3 Engineering Bacteriophage for Medical Applications -- 6.3.1 Phage-Based Biosensors for Pathogen Detection -- 6.3.2 Phage for Biomedical Imaging -- 6.3.3 Phage for Treatment of Infections (Phage Therapy) -- 6.3.4 Phage for Treating Anti-Microbial Resistance. 6.4 Engineering Bacteriophage for Biocontrol of Pathogens in Food and Agriculture -- 6.5 Future Scope -- References -- 7: CRISPR Technologies: A Tool for Engineering Microbes -- 7.1 Introduction -- 7.2 Bacterial CRISPR System -- 7.2.1 Adaptation -- 7.2.2 crRNA Maturation -- 7.2.3 Interference -- 7.2.3.1 Class 1 Interference Machinery -- 7.2.3.2 Class 2 Interference Machinery -- 7.3 Technological Overview of CRISPR/Cas9 -- 7.3.1 Genetic Engineering with CRISPR-Cas9 -- 7.3.2 Regulation of Gene Transcription by Using dCas9 -- 7.3.3 Infectious Disease Applications -- 7.3.4 Understanding Host-Pathogen Interactions -- 7.3.5 Infectious Disease Diagnostic Development -- 7.3.5.1 Diagnostics Using CRISPR-Cas9 -- 7.3.5.2 Applications Based on CRISPR/Cas12 and CRISPR/Cas13 -- 7.3.6 CRISPR-Based Therapies in the Treatment of Acute and Chronic Viral Infections -- 7.3.7 CRISPR ``Vaccines´´ -- 7.3.8 CRISPR-Based Therapies for Bacterial Infections -- 7.4 Impediments to CRISPR Therapeutics -- References -- Part III: Health Benefits -- 8: Recombinant Vaccines: The Revolution Ahead -- 8.1 Introduction -- 8.2 Vaccine Immunology -- 8.3 Herd Immunity -- 8.4 Types of Vaccines -- 8.4.1 Whole Pathogen Live-Attenuated Vaccines -- 8.4.2 Whole Pathogen Killed or Inactivated Vaccines -- 8.4.3 Subunit Vaccines -- 8.4.3.1 Toxoid Vaccines -- 8.4.3.2 Recombinant Vaccines -- Recombinant Protein-Based Vaccines -- Recombinant Virus-Like Particles -- Polysaccharide and/or Glycoconjugate Vaccines -- 8.5 New Era of Vaccinology: Shaping the Future of Immunization -- 8.5.1 Adjuvants and Novel Vaccine Delivery Systems -- 8.5.2 Bacterial and Viral Vaccine Vectors -- 8.5.3 Nucleic Acid Vaccines -- 8.5.4 Reverse and Structure-Based Vaccinology -- 8.5.5 Vaccine Development Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) -- 8.6 Clinical Trials. 8.7 Conclusion: The Challenges and Revolution Ahead -- References -- 9: Microbe-Host Metabolic Interaction: Probiotic Approach -- 9.1 Introduction -- 9.2 Probiotics -- 9.2.1 Gut Microbial Composition -- 9.2.2 Probiotics-Pathogen in the Host GIT -- 9.2.3 Immunomodulation -- 9.2.3.1 Epithelial Barrier -- 9.2.3.2 Innate Immunity -- 9.2.3.3 Adaptive Immunity -- 9.3 Probiotics in Clinical Practices -- 9.4 Gut-Brain-Immune Axis -- 9.5 Gut Microbiome and Malnutrition -- 9.6 Gut Microbiome and Covid-19 -- 9.7 Emerging Trends and Innovations -- 9.7.1 Next-Generation Probiotics -- 9.7.2 Postbiotics-Parabiotics -- 9.7.3 Faecal Microbiota Transplantation -- 9.7.3.1 Mechanism of Action of FMT on Recurrent CDI -- 9.7.4 CRISPR/Cas9 System -- 9.8 Summary and Future Perspectives -- References -- 10: Designer Microbes: Oncotherapy Approach -- 10.1 Introduction -- 10.2 Brief History of Usage of Bacteria and Virus in Oncotherapy -- 10.3 Bacterial Oncotherapy -- 10.3.1 Bacteria Producing Anti-cancer Drugs -- 10.3.1.1 Streptomyces antibioticus -- 10.3.1.2 Streptomyces verticillus -- 10.3.1.3 Streptomyces peucetius var. caesius -- 10.3.1.4 Streptomyces caespitosus -- 10.4 Probiotics in Anti-cancer Therapy -- 10.5 Microbial Engineering for Anti-cancer Therapy -- 10.5.1 Designer Bacteria in Cancer Immunotherapy -- 10.5.2 Clinical Trials of Bacterial Oncotherapy -- 10.6 Viral Oncotherapy -- 10.6.1 Viruses in Oncotherapy -- 10.6.1.1 Vaccinia Virus -- 10.6.1.2 Herpes Virus -- 10.6.2 Strategies to Improve Oncolytic Viral Therapy -- 10.7 Conclusion and Future Prospects -- References -- 11: The Human Gut Microbiome in Health, Disease, and Therapeutics -- 11.1 Introduction: The Human Gut Microbiota and Why Do We Care? -- 11.2 The Assembly of the Gut Microbiota and Their Composition -- 11.3 Impaired Gut Microbiome and Its Attribution to Chronic Diseases. 11.3.1 Inflammatory Bowel Disease (IBD). |
| Record Nr. | UNINA-9910624381503321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||